XNASCMMB
Market cap1mUSD
Dec 23, Last price
1.65USD
1D
-1.79%
1Q
5.10%
IPO
-97.20%
Name
Chemomab Therapeutics Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
79.43%
Rev. gr., 5y
%
Revenues
0k
Net income
-24m
L-12.39%
CFO
-24m
L+15.91%
Earnings
Mar 05, 2025
Profile
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 25,526 | 28,591 | 12,401 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (25,526) | (28,591) | (12,401) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (534) | 77 | |||||||
Tax Rate | |||||||||
NOPAT | (25,526) | (28,057) | (12,478) | ||||||
Net income | (24,221) -12.39% | (27,646) 120.20% | (12,555) 111.72% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 3,504 | (951) | 58,637 | ||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 76 | 123 | 106 | ||||||
Long-term debt | 708 | 305 | 580 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (19,000) | (39,465) | (60,530) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (23,611) | (20,370) | (12,374) | ||||||
CAPEX | (3) | (68) | (239) | ||||||
Cash from investing activities | 15,879 | 19,533 | (45,186) | ||||||
Cash from financing activities | 3,504 | (808) | 61,074 | ||||||
FCF | (25,627) | (27,949) | (12,600) | ||||||
| Balance | |||||||||
Cash | 19,784 | 39,893 | 61,161 | ||||||
Long term investments | 55 | ||||||||
Excess cash | 19,784 | 39,893 | 61,216 | ||||||
Stockholders' equity | (88,678) | (63,819) | (36,173) | ||||||
Invested Capital | 106,067 | 99,905 | 97,982 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 11,750 | 11,379 | 10,373 | ||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (25,459) | (28,533) | (12,367) | ||||||
EV/EBITDA | |||||||||
Interest | 353 | 111 | |||||||
Interest/NOPBT | |||||||||